450 related articles for article (PubMed ID: 25498383)
1. Calcium-sensing receptor activation in chronic kidney disease: effects beyond parathyroid hormone control.
Massy ZA; Hénaut L; Larsson TE; Vervloet MG
Semin Nephrol; 2014 Nov; 34(6):648-59. PubMed ID: 25498383
[TBL] [Abstract][Full Text] [Related]
2. Calcimimetic and calcilytic drugs for treating bone and mineral-related disorders.
Nemeth EF; Shoback D
Best Pract Res Clin Endocrinol Metab; 2013 Jun; 27(3):373-84. PubMed ID: 23856266
[TBL] [Abstract][Full Text] [Related]
3. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
4. Recent updates on the calcium-sensing receptor as a drug target.
Trivedi R; Mithal A; Chattopadhyay N
Curr Med Chem; 2008; 15(2):178-86. PubMed ID: 18220773
[TBL] [Abstract][Full Text] [Related]
5. Cinacalcet upregulates calcium-sensing receptors of parathyroid glands in hemodialysis patients.
Sumida K; Nakamura M; Ubara Y; Marui Y; Tanaka K; Takaichi K; Tomikawa S; Inoshita N; Ohashi K
Am J Nephrol; 2013; 37(5):405-12. PubMed ID: 23594726
[TBL] [Abstract][Full Text] [Related]
6. Calcium-sensing receptor, calcimimetics, and cardiovascular calcifications in chronic kidney disease.
Torres PA; De Broe M
Kidney Int; 2012 Jul; 82(1):19-25. PubMed ID: 22437409
[TBL] [Abstract][Full Text] [Related]
7. New insights into the role of calcium-sensing receptor activation.
Cozzolino M; Mazzaferro S; Messa P
J Nephrol; 2011; 24 Suppl 18():S38-41. PubMed ID: 21623581
[TBL] [Abstract][Full Text] [Related]
8. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney disease.
Quarles LD
Kidney Int Suppl; 2005 Jul; (96):S24-8. PubMed ID: 15954947
[TBL] [Abstract][Full Text] [Related]
9. Cinacalcet in hyperfunctioning parathyroid diseases.
Imanishi Y; Inaba M; Kawata T; Nishizawa Y
Ther Apher Dial; 2009 Oct; 13 Suppl 1():S7-S11. PubMed ID: 19765257
[TBL] [Abstract][Full Text] [Related]
10. Sensing Extracellular Calcium - An Insight into the Structure and Function of the Calcium-Sensing Receptor (CaSR).
Chavez-Abiega S; Mos I; Centeno PP; Elajnaf T; Schlattl W; Ward DT; Goedhart J; Kallay E
Adv Exp Med Biol; 2020; 1131():1031-1063. PubMed ID: 31646544
[TBL] [Abstract][Full Text] [Related]
11. Calcimimetic agents and secondary hyperparathyroidism: rationale for use and results from clinical trials.
Goodman WG
Pediatr Nephrol; 2003 Dec; 18(12):1206-10. PubMed ID: 14586685
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a calcimimetic with differential effects on parathyroid hormone and calcitonin secretion.
Henley C; Yang Y; Davis J; Lu JY; Morony S; Fan W; Florio M; Sun B; Shatzen E; Pretorius JK; Richards WG; St Jean DJ; Fotsch C; Reagan JD
J Pharmacol Exp Ther; 2011 Jun; 337(3):681-91. PubMed ID: 21422163
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic agents for disorders of bone and calcium metabolism. The calcimimetic cinacalcet HCl].
Nakanishi S; Fukagawa M
Clin Calcium; 2007 Jan; 17(1):88-92. PubMed ID: 17211098
[TBL] [Abstract][Full Text] [Related]
14. Calcimimetics and hyperparathyroidism.
Krebs LJ
Curr Opin Investig Drugs; 2004 Oct; 5(10):1080-5. PubMed ID: 15535429
[TBL] [Abstract][Full Text] [Related]
15. Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism.
Kawata T; Imanishi Y; Kobayashi K; Kenko T; Wada M; Ishimura E; Miki T; Nagano N; Inaba M; Arnold A; Nishizawa Y
Eur J Endocrinol; 2005 Oct; 153(4):587-94. PubMed ID: 16189180
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism.
Nagano N
Pharmacol Ther; 2006 Mar; 109(3):339-65. PubMed ID: 16102839
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological profile of upacicalcet, a novel positive allosteric modulator of calcium-sensing receptor, in vitro and in vivo.
Goto M; Nishimura G; Sato H; Yamaguchi Y; Morimoto N; Hashimoto H; Takahashi N
Eur J Pharmacol; 2023 Oct; 956():175936. PubMed ID: 37541363
[TBL] [Abstract][Full Text] [Related]
18. Functional proteins involved in regulation of intracellular Ca(2+) for drug development: the extracellular calcium receptor and an innovative medical approach to control secondary hyperparathyroidism by calcimimetics.
Nagano N; Nemeth EF
J Pharmacol Sci; 2005 Mar; 97(3):355-60. PubMed ID: 15781990
[TBL] [Abstract][Full Text] [Related]
19. The Use of Calcimimetics for the Treatment of Secondary Hyperparathyroidism: A 10 Year Evidence Review.
Rodríguez M; Goodman WG; Liakopoulos V; Messa P; Wiecek A; Cunningham J
Semin Dial; 2015; 28(5):497-507. PubMed ID: 25752650
[TBL] [Abstract][Full Text] [Related]
20. Allosteric modulators of the extracellular calcium receptor.
Nemeth EF
Drug Discov Today Technol; 2013; 10(2):e277-84. PubMed ID: 24050279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]